Payment overview · 2025
General Payments
$1,383.12
84 reported records · 17 companies
Healthcare provider profile · identity verified
Stuart E Mishelof, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · CHICO, CA · NPI 1821300534
Verified facts
What the public records show
CMS Open Payments records show Stuart E Mishelof, P.A. received $1,383.12 in general payments during 2025 across 84 reported records.
ABBVIE INC. accounted for 48.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Paxlovid, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $669.99 | 48.4% | 46 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $152.42 | 11.0% | 7 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $66.40 | 4.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.43 | 4.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.10 | 4.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $55.02 | 4.0% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $54.07 | 3.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.00 | 3.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.41 | 3.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.76 | 2.5% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $27.29 | 2.0% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.62 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.70 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.06 | 1.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.57 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.48 | 1.2% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $14.80 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,383.12 | 84 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $564.40 | 38 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $560.54 | 38 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $108.83 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.43 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $66.40 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.43 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $64.43 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.02 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $54.07 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $46.00 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.59 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.59 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.31 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $41.30 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.99 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.76 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $33.60 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $28.08 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.08 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 47 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
138 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
47 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 471 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 388 | 103 |
| Losartan Potassium | Losartan Potassium | 263 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 236 | 40 |
| Lisinopril | Lisinopril | 221 | 63 |
| Metformin Hcl | Metformin Hcl | 214 | 72 |
| Omeprazole | Omeprazole | 199 | 61 |
| Tramadol Hcl | Tramadol Hcl | 180 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 50 |
| Montelukast Sodium | Montelukast Sodium | 152 | 42 |
| Gabapentin | Gabapentin | 140 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 33 |
| Mounjaro | Tirzepatide | 138 | 18 |
| Alprazolam | Alprazolam | 132 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 33 |
| Furosemide | Furosemide | 117 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 37 |
| Azithromycin | Azithromycin | 111 | 91 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 24 |
| Methylprednisolone | Methylprednisolone | 102 | 81 |
| Trazodone Hcl | Trazodone Hcl | 101 | 27 |
| Potassium Chloride | Potassium Chloride | 91 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 30 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 89 | 70 |
| Meloxicam | Meloxicam | 84 | 26 |
| Carvedilol | Carvedilol | 80 | 20 |
| Sertraline Hcl | Sertraline Hcl | 80 | 19 |
| Alendronate Sodium | Alendronate Sodium | 72 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 17 |
| Lorazepam | Lorazepam | 66 | 17 |
| Allopurinol | Allopurinol | 64 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 64 | 64 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 12 |
| Trulicity | Dulaglutide | 63 | suppressed |
| Bupropion Xl | Bupropion Hcl | 60 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 39 |
| Eliquis | Apixaban | 55 | 13 |
| Simvastatin | Simvastatin | 54 | 15 |
| Baclofen | Baclofen | 53 | 13 |
| Prednisone | Prednisone | 53 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 50 | suppressed |
| Atenolol | Atenolol | 48 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 47 | 47 |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 14 |
| Famotidine | Famotidine | 43 | 14 |
| Pregabalin | Pregabalin | 43 | 15 |
| Synthroid | Levothyroxine Sodium | 41 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Cephalexin | Cephalexin | 37 | 27 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Estradiol | Estradiol | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 12 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Oxycontin | Oxycodone Hcl | 33 | suppressed |
| Finasteride | Finasteride | 32 | 12 |
| Levofloxacin | Levofloxacin | 32 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 27 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Ramipril | Ramipril | 21 | suppressed |
| Armour Thyroid | Thyroid,pork | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 11 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Glyburide | Glyburide | 16 | suppressed |
| Methadone Hcl | Methadone Hcl | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,383.12 · 84 records | ABBVIE INC. | AIRSUPRA, CREON, Dexcom G6 Transmitter, EVENITY, FARXIGA, GEMTESA, INJECTAFER, JARDIANCE, JOURNAVX, Kerendia, LINZESS, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PROLIA, QULIPTA, REPATHA, Rybelsus, Tlando, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error